Recent Articles in Deals & Financings

Sino Biopharm was approved to close its $161 million all-cash acquisition of F-Star, a Cambridge, UK company that develops bispecific antibodies. The purchase didn't look like would happen after it was held up for nine months by the US government’s Committee on Foreign Investment in the United States (CFIUS), which aims to slow China’s acquisition of advanced US technologies. F-Star, which has a NASDAQ listing and a US subsidiary in Cambridge, MA, develops bispecific drugs for immunotherapies using tetravalent (2+2) bispecific antibodies. More details....

Stock Symbols: (HK: 1177) (NSDQ: FSTX)

Share this with colleagues:

Rinua Gene, a Suzhou startup, closed a Pre-A+ funding worth $14.5 million to develop mRNA drugs. The company has built a data-based technology platform focused on cutting-edge delivery and efficient production that is led by mRNA drug development. Rinua Gene says it has advanced multiple products to the IND approval stage from its three technology platforms: linear mRNA, cyclic mRNA and novel LNP-targeted delivery. Using these platforms, the company will conduct R&D of preventive vaccines for infectious diseases, tumor-related therapeutic vaccines and protein replacement products. The round was led by the Dechuan Medical Fund. More details....

Stock Symbol: 

Share this with colleagues:  

Shanghai Abbisko Therapeutics out-licensed Greater China rights to a pre-clinical EGFR-TKI candidate for NSCLC to Shanghai Allist Pharma in a $188 million agreement. ABK3376 is a third-gen EGFR targeting drug designed to inhibit L858R activating mutation or exon 19 deletion mutation with acquired C797S mutation. Because the candidate can cross the blood-brain barrier, it is also expected to be effective against brain metastases. Allist is already commercializing Abbisko’s furmonertinib, an approved NSCLC drug in China. Allist also has a time-limited option for worldwide expansion of territorial rights for ABK3376. More details....

Stock Symbols: (HK: 02256) (SHA: 688578)

Share this with colleagues:  

Suzhou TandemAI, a drug discovery company, closed a $35 million Series A round to expand its platform that integrates breakthrough computational tools with wet lab biophysics, medicinal chemistry and biology. Established in 2021, TandemAI was formed with the goal of lowering the barrier to entry for drug discovery’s most advanced tools, including physics-based molecular simulation, AI and access to high performance computing infrastructure. The company completed a $25 million Seed and pre-Series A financing in late 2021. Qiming Venture Partners led the financing along with participation from OrbiMed, Eight Roads Ventures and F Prime Capital. More details....

Share this with colleagues:  

Immorna, a Hangzhou company developing novel RNA therapeutic and vaccine candidates, raised $100 million in a Series A+/A++ funding to support clinical development of its portfolio. Founded in 2019, the company has built multiple RNA platforms for conventional, self-replicating and circular RNA technologies. With its advanced screening tools, Immorna has developed several RNA delivery vehicles. Immorna has a total of 11 RNA candidates that target indications in cancer immunotherapy, infectious diseases, rare genetic diseases and cosmology. The company has approval to start three clinical trials for two assets in the US. More details....

Share this with colleagues: